%0 Journal Article
%T Erlotinib plus bevacizumab for  EGFR -mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?
%A Christoph Jakob Ackermann
%A Helen Adderley
%A Raffaele Califano
%J SCIE-indexed Journal
%D 2019
%R 10.21037/atm.2019.09.116
%X EGFR tyrosine kinase inhibitors (TKIs) represent the standard of care for first-line treatment for patients with advanced EGFR mutant non-small cell lung cancer (NSCLC) with superiority in overall response rate (ORR), progression free survival (PFS) and quality of life compared to platinum-based chemotherapy (ChT) (1)
%U http://atm.amegroups.com/article/view/30081/html